News

FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.

The COLIBRI study reveals that neoadjuvant dual immune checkpoint blockade enhances treatment outcomes for locally advanced cervical cancer, showing promising immune responses.

NCCN updates guidelines to include sacituzumab govitecan as a first-line treatment for metastatic triple-negative breast cancer, enhancing patient options.

Precision medicine revolutionizes endometrial cancer treatment, emphasizing molecular drivers and the challenges of next-generation sequencing in clinical decision-making.

A new clinical trial evaluates survival outcomes for recurrent head and neck cancer, comparing surgery with neoadjuvant chemotherapy and immunotherapy.

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating patients with advanced rectal cancer with high Immunoscores.

Nutritional status significantly impacts survival and treatment outcomes in cervical cancer patients, highlighting the need for routine nutritional screening.

The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.

New clinical data reveals Bria-IMT's potential to significantly extend survival in patients with heavily pretreated metastatic breast cancer, offering hope for better outcomes.

Phase 2 trial shows abemaciclib prolongs disease control in recurrent high‑grade meningioma with NF2/CDK alterations, with 58% PFS at 6 months.

FDA approves D-VRd, a groundbreaking treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, enhancing survival rates.

Atebimetinib shows promising 1-year survival rates in pancreatic cancer patients, potentially transforming treatment options with manageable safety profiles.

The FDA awarded fast track designation to a trispecific antibody targeting BCMA, GPRC5D, and CD3 in multiple myeloma.

Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

New findings reveal that tafasitamab significantly enhances progression-free survival in relapsed follicular lymphoma when combined with lenalidomide and rituximab.

The FDA gave clearance to the IND for a randomized trial of the DNA vaccine iSCIB1+ based on positive single-arm data in combination with dual checkpoint inhibitors.

Experts discuss second-line treatment strategies for clear cell renal cell carcinoma, focusing on efficacy, tolerability, and the role of tivozanib.

New research reveals comparable outcomes for STZ/5-FU and everolimus in treating advanced pancreatic neuroendocrine tumors, guiding personalized treatment strategies.

Higher doses of anti–T-lymphocyte globulin significantly reduce chronic graft-vs-host disease in matched sibling stem cell transplants, enhancing patient outcomes.

Deb Schrag, MD, emphasizes AI's role in enhancing cancer care, addressing early-onset cancers, and improving workforce well-being as she prepares for ASCO leadership.

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

Discover the latest breakthroughs in oncology, including FDA approvals and promising trial results for advanced breast cancer and metastatic colorectal cancer.

During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of innovative CLL treatment combinations.

Researchers explore a promising nonchemotherapy treatment for low-grade serous ovarian cancer, combining ribociclib and letrozole to improve patient outcomes.

The ROSELLA trial reveals relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant ovarian cancer without increasing safety risks.

FDA approves Guardant360 CDx for identifying BRAF V600E-mutant colorectal cancer patients, enhancing precision therapy with encorafenib and cetuximab.

Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to improving patient outcomes.